APO-RANITIDINE TABLET 300MG 300 MG — DIN 00733067
RANITIDINE (RANITIDINE HYDROCHLORIDE) : 300 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is APO-RANITIDINE TABLET 300MG?
APO-RANITIDINE TABLET 300MG 300 MG contains RANITIDINE (RANITIDINE HYDROCHLORIDE) : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 00733067, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 13-Sep-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is APO-RANITIDINE TABLET 300MG used for?
APO-RANITIDINE (ranitidine hydrochloride) is indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence; the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients; the prophylaxis of recurrent hemorrhage from bleeding ulcers; the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, APO-RANITIDINE is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ranitidine cost around the world?
Ranitidine is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Morocco publishes a PPV (public price); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 40 | 58 | SAR███.██ |
| South Africa | single exit price | 31 | 42 | ZAR███.██ |
| Morocco | PPV (public price) | 8 | 32 | MAD███.██ |
| Australia | ex-manufacturer | 3 | 4 | AUD███.██ |
136 pack listings across 82 brand entries and 4 price bases, refreshed 08 Sep 2026. Ranges span every Ranitidine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Ranitidine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
36 holders have a Canadian DIN containing Ranitidine, across 96 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MARCAN PHARMACEUTICALS INC | 2 | 2 | MAR-RANITIDINE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 2 | 2 | MINT-RANITIDINE | Sourceable in Canada |
| PHARMASCIENCE INC | 8 | 1 | ACID REDUCER, MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION, PMS-RANITIDINE 150 MG, PMS-RANITIDINE 300 MG, RANITIDINE, +2 more | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 7 | 0 | ACID REDUCER, ACID REDUCER MAXIMUM STRENGTH NON-PRESCRIPTION, MYL-RANITIDINE, MYLAN-RANITIDINE, RANITIDINE | No marketed DIN |
| GLAXO CANADA INC | 6 | 0 | ZANTAC, ZANTAC ORAL SOLUTION 15MG/ML, ZANTAC TAB 150MG, ZANTAC TAB 300MG, ZANTAC-C CAP 150MG, +1 more | No marketed DIN |
| TEVA CANADA LIMITED | 6 | 0 | ACT RANITIDINE, TEVA-RANITIDINE, TEVA-RANITIDINE INJECTION, TEVA-RANITIDINE SOLUTION | No marketed DIN |
| APOTEX INC | 5 | 0 | ACID REDUCER, APO-RANITIDINE, APO-RANITIDINE TABLET 150MG, APO-RANITIDINE TABLET 300MG | No marketed DIN |
| GLAXOSMITHKLINE INC | 4 | 0 | ZANTAC | No marketed DIN |
| RANBAXY PHARMACEUTICALS CANADA INC. | 4 | 0 | RAN-RANITIDINE, RANITIDINE TABLETS | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 4 | 0 | RANITIDINE INJECTION USP, RANITIDINE NON PRESCRIPTION, SANDOZ RANITIDINE | No marketed DIN |
| DOMINION PHARMACAL | 3 | 0 | DOM-RANITIDINE, MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION | No marketed DIN |
| VITA HEALTH PRODUCTS INC | 3 | 0 | ACID REDUCER, MAXIMUM STRENGTH ACID REDUCER | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 150 mg: bottles of 60, 100 and 500 tablets and in unit dose packages of 60 and 100. 300 mg: bottles of 30, 100 and 500 tablets and in unit dose packages of 30 and 100. |
| Storage | Store between 15°C - 30°C (59°F - 86°F). Protect from light. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Ranitidine |
|---|---|
| ATC code | A02BA02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00733067 |
|---|---|
| DIN (unpadded, as printed on some documents) | 733067 |
| Brand name | APO-RANITIDINE TABLET 300MG |
| Generic / active ingredient | RANITIDINE (RANITIDINE HYDROCHLORIDE) : 300 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | A02BA02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02BA |
| Current status | DORMANT |
| Status date | 13-Sep-2020 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 96 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-RANITIDINE | 150 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02443708 |
| MAR-RANITIDINE | 300 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02443716 |
| MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02293471 |
| MINT-RANITIDINE | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02526387 |
| MINT-RANITIDINE | 150 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02526379 |
| ACID REDUCER | 75 MG | TABLET | WESTCAN PHARMACEUTICALS LTD. | CANCELLED PRE MARKET | 02240348 |
| ACID REDUCER | 75 MG | TABLET | APOTEX INC | DORMANT | 02230507 |
| ACID REDUCER | 75.0 MG | TABLET | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | CANCELLED POST MARKET | 02241422 |
| ACID REDUCER | 75 MG | TABLET | PHARMASCIENCE INC | DORMANT | 02247551 |
| ACID REDUCER | 150 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | APPROVED | 02291282 |
2 · Same class — other molecules in ATC A02BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Famotidine | ACID CONTROL · ACID CONTROLLER MAXIMUM STRENGTH · ACT · AG-FAMOTIDINE · +39 more | 68 | 17 | Yes |
| Ranitidine | ACID REDUCER · ACID REDUCER MAXIMUM STRENGTH NON-PRESCRIPTION · ACT RANITIDINE · AG-RANITIDINE · +46 more | 96 | 5 | Yes |
| Cimetidine | APO-CIMETIDINE ORAL SOLUTION · CIMETIDINE · CIMETIDINE 200 TAB 200MG · CIMETIDINE TAB 300MG · +27 more | 50 | 2 | Yes |
| Nizatidine | APO-NIZATIDINE · AXID · DOM-NIZATIDINE 150MG CAPSULES · GEN-NIZATIDINE · +7 more | 19 | 1 | Yes |
| Famotidine, Combinations | PEPCID COMPLETE | 1 | 1 | Yes |
| Ranitidine Bismuth Citrate | PYLORID | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A02BC | Dexlansoprazole · Esomeprazole · Lansoprazole · Omeprazole · Pantoprazole · +1 more | 288 | 108 |
| A02BX | Alginic Acid · Pirenzepine · Sucralfate | 32 | 4 |
| A02BB | Misoprostol | 10 | 2 |
| A02BD | Bismuth Subcitrate,Tetracycline And Metronidazole · Lansoprazole, Amoxicillin And Clarithromycin | 3 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-RANITIDINE TABLET 300MG called?
The same molecule, Ranitidine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ZANTAC | Latin | Morocco, Saudi Arabia |
| EFITAC | Latin | Morocco |
| AZANTAC | Latin | Morocco |
| RANITIL | Latin | Morocco |
| ACICARE | Latin | Saudi Arabia |
| ACIDAC | Latin | Morocco |
| NORMACIDE | Latin | Morocco |
| RANIMAT | Latin | Morocco |
| APO-Ranitidine | Latin | Australia |
| PEP-RANI | Latin | Morocco |
| RANIMAX AC TABLET | Latin | Saudi Arabia |
| Ranit | Latin | South Africa |
| R-loc Injection | Latin | South Africa |
| Ranitidine Injection Pharma-Q | Latin | South Africa |
| Zantac Syrup | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.